Vmbook Online ordering

Medical Appliances Equipment

**Cardiovascular Systems, Inc. (CSII)**

**General Information**

* Industry: Medical Devices

* Sector: Healthcare

* Headquarters: St. Paul, Minnesota, USA

* Stock Symbol: CSII (Nasdaq)

**Key Metrics**

* Market Cap: $1.3 billion (as of March 8, 2023)

* Revenue: $268.4 million (2022)

* Net Income: $42.9 million (2022)

* Earnings per Share (EPS): $2.24 (2022)

**Business Overview**

Cardiovascular Systems, Inc. (CSI) is a medical device company that develops, manufactures, and markets innovative solutions for the treatment of vascular and cardiac diseases. Its primary products include:

* Orbital Atherectomy System (OAS): A minimally invasive device used to remove plaque from arteries.

* Diamondback 360 Peripheral Orbital Atherectomy System: A next-generation OAS with enhanced capabilities.

* Excimer Laser System: A device used to treat coronary artery disease by removing plaque and creating a new lumen.

**Earnings and Growth**

* **Revenue:** CSI's revenue has grown steadily in recent years, with a 5-year compound annual growth rate (CAGR) of 10.5%.

* **Net Income:** Net income has also shown consistent growth, with a 5-year CAGR of 14.7%.

* **EPS:** EPS has grown at a slightly faster rate than net income, with a 5-year CAGR of 16.1%.

**Valuation**

* **Price-to-Earnings (P/E) Ratio:** CSI's P/E ratio is currently around 20.5, which is higher than the industry average.

* **Price-to-Sales (P/S) Ratio:** The P/S ratio is around 5.2, which is also higher than the industry average.

**Outlook**

CSI is well-positioned for continued growth in the future. The company has a strong pipeline of new products, including the Diamondback 360 Peripheral Orbital Atherectomy System, which is expected to drive future revenue. Additionally, the increasing prevalence of vascular and cardiac diseases is expected to create a growing market for CSI's products.